| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 490 | 310 | 430 | 620 | 560 |
| Sales Growth | +58.06% | -27.91% | -30.65% | +10.71% | +3.70% |
| Net Income | -23,020 | -29,240 | -22,210 | -20,830 | -21,860 |
| Net Income Growth | +21.27% | -31.65% | -6.63% | +4.71% | -12.45% |
Anteris Technologies Global Corp (AVR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Anteris Technologies Global Corp. is involved in designing, developing and commercializing cutting-edge medical devices to restore healthy heart function. The company's lead product includes DurAVR(R). Anteris Technologies Global Corp. is based in BRISBANE, Australia.
Fiscal Year End Date: 12/31